Komori
Mitsubishi Chemical Group (4188) · RiskRestated

Arbitration over Gilenya royalties and revenue recognition risk

First written in FY2019. 9 of 15 entries say "Restated". Latest entry: FY2024-Q3.

15entries
6years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseMaterialisedFY2019 – FY2020-Q1RestatedFY2020 – FY2022-Q2MaterialisedFY2023-Q1 – FY2023-Q3RestatedFY2024-Q1 – FY2024-Q32019: 220192020: 220202021: 420212022: 220222023: 420232024: 1
Same theme, other companies
Uncertainty over revenue recognition arising from the Gilenya royalty arbitrationA theme 1 companies write about · 1 as a headwind · 0 as a tailwind

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  1. FY2024-Q3RestatedAnnual report

    「As a result of the arbitral tribunal's decision in February 2023 that all provisions of the Agreement were valid, revenue of ¥125,883 million was recognized in the fourth quarter of the previous consolidated fiscal year, and revenue has continued to be recognized thereafter.」

    Regarding the arbitration over Gilenya royalties, the company reconfirmed that, following the arbitral ruling, the previously unrecognized amount was recognized in the fourth quarter of the previous fiscal year and revenue has continued to be recognized thereafter.
  2. FY2024-Q2RestatedAnnual report

    「In addition to sales of the products mentioned above, the company receives royalty and other income. With respect to royalty income from Gilenya®, a treatment for multiple sclerosis licensed to Novartis Pharma AG of Basel, Switzerland, in the pharmaceutical business of the Healthcare segment, the company had not recognized part of the royalty income as revenue under IFRS 15 since arbitration proceedings began in February 2019. Following the arbitral tribunal's determination in February 2023 that all provisions of the contract were valid, the company recognized revenue of ¥125,883 million in the fourth quarter of the previous consolidated fiscal year and has continued to recognize revenue thereafter.」

    Regarding Gilenya royalties, the company reconfirmed that, following the arbitration ruling in February 2023, the previously unrecognized amount was recognized in the fourth quarter of the previous fiscal year and revenue has continued to be recognized thereafter.
  3. FY2024-Q1RestatedAnnual report

    「In addition to sales of the products mentioned above, the company receives royalty and other income. With respect to royalty income from Gilenya®, a treatment for multiple sclerosis licensed to Novartis Pharma AG of Basel, Switzerland, in the pharmaceutical business of the Healthcare segment, the company had not recognized part of the royalty income as revenue under IFRS 15 since arbitration proceedings began in February 2019. Following the arbitral tribunal's determination in February 2023 that all provisions of the contract were valid, the company recognized revenue of ¥125,883 million in the fourth quarter of the previous consolidated fiscal year and has continued to recognize revenue thereafter.」

    Regarding the arbitration over Gilenya royalties, the company reconfirmed that, following the determination in February 2023, the previously unrecognized amount was recognized in the fourth quarter of the previous fiscal year and royalty income has continued to be recognized thereafter.
  4. FY2023MitigatedAnnual report

    「Following the arbitral tribunal's determination that all provisions of the contract were valid, the company recognized revenue of ¥125.9 billion in the fourth quarter of the current consolidated fiscal year.」

    Regarding the arbitration over Gilenya royalties, the company recognized ¥125.9 billion of previously unrecognized royalties as revenue following the arbitral tribunal's determination that all contractual provisions were valid.
  5. FY2023-Q3MaterialisedAnnual report

    「Loss on arbitration award 3,542」

    Regarding the arbitration over Gilenya royalties, the company recognized a loss of ¥3,542 million during the nine-month period of the current consolidated fiscal year in connection with the arbitral award. As the arbitration proceedings remained ongoing, it continued not to recognize part of the royalty income as revenue.
  6. FY2023-Q2MaterialisedAnnual report

    「Loss on arbitration award 3,502」

    Regarding the arbitration over Gilenya royalties, the company recognized a loss of ¥3,502 million during the six-month period of the current consolidated fiscal year in connection with the arbitral award. However, because the arbitration proceedings remained ongoing, it continued not to recognize part of the royalty income as revenue.
  7. FY2023-Q1MaterialisedAnnual report

    「Loss on arbitration award 3,398」

    Regarding the arbitration over Gilenya royalties, the company recognized a loss of ¥3,398 million in the first quarter in connection with the arbitral award. However, because the arbitration proceedings remained ongoing, it continued not to recognize part of the royalty income as revenue.
  8. FY2022-Q2RestatedAnnual report

    「As the arbitration proceedings remained ongoing during the six-month period of the current consolidated fiscal year, the company did not recognize part of the royalty income as revenue.」

    The arbitration proceedings over Gilenya royalties and the continued non-recognition of part of the royalties as revenue remain ongoing.
  9. FY2022-Q1RestatedAnnual report

    「As the arbitration proceedings were still ongoing during the current first-quarter cumulative period, part of the royalty income was not recognized as revenue.」

    The arbitration proceedings over Gilenya royalties and the continued non-recognition of part of the royalties as revenue remain ongoing.
  10. FY2021RestatedAnnual report

    「As the arbitration proceedings remained ongoing during the current consolidated fiscal year, the company did not recognize part of the royalty income as revenue.」

    The arbitration proceedings over Gilenya royalties and the non-recognition of part of the revenue continued.
  11. FY2021-Q3RestatedAnnual report

    「As the arbitration proceedings were still ongoing during the current third-quarter cumulative period, part of the royalty income was not recognized as revenue.」

    The arbitration proceedings over Gilenya royalties and the continued non-recognition of part of the royalties as revenue remain ongoing.
  12. FY2021-Q1RestatedAnnual report

    「As the arbitration proceedings were still ongoing during the current first-quarter cumulative period, part of the royalty income was not recognized as revenue.」

    The arbitration proceedings over Gilenya royalties and the continued non-recognition of part of the royalties as revenue remain ongoing.
  13. FY2020RestatedAnnual report

    「As the arbitration proceedings remained ongoing during the current consolidated fiscal year, the company continued not to recognize part of the royalties as revenue.」

    The arbitration proceedings over Gilenya royalties and the continued non-recognition of part of the royalties as revenue remain ongoing.
  14. FY2020-Q1MaterialisedAnnual report

    「Although domestic prescription pharmaceuticals, led by key products, increased, revenue and core operating profit both declined due to lower royalty income and other factors. With respect to royalty income from Gilenya, a treatment for multiple sclerosis licensed to Novartis Pharma AG of Switzerland, the company did not recognize part of the royalty income as revenue in accordance with IFRS 15 because arbitration proceedings began in February 2019. As the arbitration proceedings remained ongoing during the quarter, the company continued not to recognize the revenue, resulting in lower revenue.」

    The arbitration proceedings over Gilenya royalties continued, and the non-recognition of part of the royalty income as revenue continued during the quarter.
  15. FY2019MaterialisedAnnual report

    「Tanabe Mitsubishi Pharma Co., Ltd., a consolidated subsidiary of the company, received a notice of arbitration from Novartis Pharma AG in February 2019. Novartis claims that certain provisions of the licence agreement concluded with the company in 1997 are invalid and that Novartis is not obligated to pay part of the royalties.」

    The company received a notice of arbitration from Novartis in February 2019 regarding the licence agreement for Gilenya. In connection with the arbitration proceedings, it stated that part of the royalties would not be recognized as revenue under IFRS 15.
Moved together

"Earnings volatility arising from demand, market conditions, raw material prices, foreign exchange and supply constraints" moved the same way as this thread, in the same document, in 5 of its 15 moves.

54333★12345
  1. ★This thread
  2. 1Earnings volatility arising from demand, market conditions, raw material prices, foreign exchange and supply constraints5×
  3. 2Funding risks from interest-bearing debt, interest rates and credit-rating downgrades4×
  4. 3Deteriorating profitability and impairment at petrochemical and materials facilities3×
  5. 4Pharmaceutical business risks related to drug price revisions, new drug development, competition and adverse reactions3×
  6. 5FY2022 consolidated earnings outlook3×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for Mitsubishi Chemical Group yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.